SLATE-ASSET-MANAGEMENT
22.7.2022 08:02:07 CEST | Business Wire | Press release
Slate Asset Management (“Slate”), a global alternative investment platform targeting real assets, today announced that it has acquired a majority stake in amperio GmbH (“amperio”), a specialist planner and operator of electric vehicle (“EV”) charging infrastructure in Germany.
Amperio is a leading planner and operator of EV charging stations in the highly-fragmented EV charging market in Germany. Since 2012, amperio has been supporting companies, cities, and communities in developing tailored charging concepts, installing charging stations, and providing backend management services for charging stations. To date, amperio has installed over 1,800 intelligent charging points. Amperio maintains, operates, and executes the billing for over 300 of these charging points on behalf of its customers.
As part of the transaction, Slate created Slate Mobility GmbH & Co. KG (“Slate Mobility”), an entity that will finance and own EV charging equipment for Slate and potential third parties and receive management services from amperio. Slate’s portfolio of over 225 grocery properties across Germany and deep network of relationships with tenants focused on environmental sustainability will create a pipeline of opportunities to accelerate amperio’s growth.
Amperio, together with Move About Groups subsidiary mobileeee GmbH (“mobileeee”) and the City of Ludwigshafen in Germany, are implementing a project for station-based public e-carsharing. The project includes the build-up of 27 stations with mobileeee charging infrastructure as well as publicly accessible charging infrastructure. The City Ludwigshafen initiated this concept with the aim of reducing local emissions in the City and its districts.
“To achieve the German government’s target of having at least 15 million electric cars on the roads by 2030 will require significant investment in EV charging points throughout the country,” said Christian Schmid, Managing Director and Global Head of Infrastructure at Slate. “Amperio is offering a unique, customizable national product to help meet this demand, backed by a team with a proven track record of experience developing charging infrastructure for cities, communities, and businesses. We are excited to partner with amperio to enhance the sustainability infrastructure of our own properties and improve access to efficient charging points all across Germany.”
“Our partnership with Slate presents an exciting opportunity to scale our business and provide seamless and sustainable mobility solutions that are so urgently needed to protect the climate,” added Oliver P. Kaul, Managing Director of amperio. “Our environment has given us the assignment to create zero-emission mobility. Slate has offered us its properties and the funding to accelerate that mission, which amperio embarked on 10 years ago. Together, we strive to achieve our goal of making clean EV charging technology and services widely available.”
Slate is an active investor in sustainable assets and technologies that advance the global energy transition and enable cities and communities to reach their carbon emission reduction goals. Slate’s most recent impact infrastructure investment was a commitment to Eider VF Limited, a UK-based vertical farming business sustainably growing leafy produce to be sold to the UK mass market.
About Slate Asset Management
Slate Asset Management is a global alternative investment platform targeting real assets. We focus on fundamentals with the objective of creating long-term value for our investors and partners. Slate’s platform has a range of real estate and infrastructure investment strategies, including opportunistic, value add, core plus and debt investments. We are supported by exceptional people and flexible capital, which enable us to originate and execute on a wide range of compelling investment opportunities.
Visit slateam.com to learn more.
About amperio
amperio GmbH is a specialist planner for charging infrastructure based in Cologne. Since 2012, amperio has been supporting companies, cities and municipalities in developing individual charging concepts, installing charging stations and billing charging processes. In doing so, amperio relies on a holistic service that leaves no customer wishes unfulfilled. This includes location analysis, profitability analysis, business model analysis, technical consulting, backend service (monitoring and billing), the operation of charging points, and energy management and subsidy consulting. In addition, amperio offers two charging infrastructure concepts developed in-house with its CHARGE2GO and Mitarbeiter-Strom products. The company has already installed over 1,800 charging points for customers such as Globus, DKB, Groupe PSA, the city of Düren, Volvo, the city of Bad Ems and the MNT Group.
amperio GmbH is part of Slate Asset Management, a global alternative investment platform, which holds a majority stake in amperio GmbH.
Visit amperio.eu to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005973/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom